HomeClinical TopicsFDA approves two drugs for idiopathic pulmonary fibrosis

FDA approves two drugs for idiopathic pulmonary fibrosis

On Oct. 15, the U.S. Food and Drug Administration (FDA) approved Ofev (nintedanib) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm and Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis. Read more about nintedanib and prifenidone http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content